BioSpace News Archive

CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA.
GVK Biosciences

GVK Biosciences is now Aragen Bioscience.
Business

Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria

Following in the footsteps of Sanofi and Moderna, Eli Lilly on Tuesday inked a collaboration agreement with OpenAI to develop novel antimicrobial agents against drug-resistant pathogens.

June 26, 2024
·
2 min read
·
Tristan Manalac
Policy

Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade

Teva Pharmaceuticals has settled years of tax litigation with the Israel Tax Authority for $750 million, which the company will pay in installments starting in 2024 to 2029.

June 26, 2024
·
2 min read
·
Tristan Manalac
Business

Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic

The biotech incubator said Wednesday the majority of the fund will be for clinical proof-of-concept studies, bringing the total funds raised by Curie.Bio to nearly $1 billion.

June 26, 2024
·
1 min read
·
Kate Goodwin
Drug Development

Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval

After back-to-back failures in 2021, Wave Life Sciences has finally aced a Phase Ib/IIa Huntington’s disease trial and is looking to a potential accelerated approval for its investigational antisense oligonucleotide.

June 26, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Zealand to Raise $1B in Public Offering to Fund Obesity Candidates

Zealand Pharma is looking to build on last week’s positive Phase Ib trial results by raising around $1 billion in a public offering, with the proceeds being used to advance its obesity candidates.

June 26, 2024
·
1 min read
·
Tyler Patchen
Drug Development

Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate

One patient died of respiratory failure in a Phase I study of Lyell Immunopharma’s investigational CAR-T therapy. The company on Wednesday said it has not definitively linked the fatality to the treatment.

June 26, 2024
·
2 min read
·
Tristan Manalac
Job Trends

5 Top Companies Hiring in the Washington, D.C., Area

Looking for a biopharma job in or near Washington, D.C.? Check out these five top companies hiring life sciences professionals like you.

June 26, 2024
·
1 min read
·
Angela Gabriel
Business

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Valneva SE announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting held in Lyon, France.

June 26, 2024
·
4 min read